Prothena Corporation plc (Nasdaq: PRTA) is a late-stage clinical biotechnology company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapies with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Prothena leverages insights into the biology of misfolded proteins to develop novel therapeutic solutions that directly target pathogenic proteins in order to change the course of devastating diseases.
Learn More